Stocks and Investing Stocks and Investing
Thu, April 30, 2020

Matthew Harrison Maintained (VRTX) at Buy with Increased Target to $277 on, Apr 30th, 2020


Published on 2024-10-27 04:37:18 - WOPRAI, Matthew Harrison
  Print publication without navigation


Matthew Harrison of Morgan Stanley, Maintained "Vertex Pharmaceuticals Incorporated" (VRTX) at Buy with Increased Target from $258 to $277 on, Apr 30th, 2020.

Matthew has made no other calls on VRTX in the last 4 months.



There are 7 other peers that have a rating on VRTX. Out of the 7 peers that are also analyzing VRTX, 2 agree with Matthew's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Brian Abrahams of "RBC Capital" Downgraded from Buy to Hold and Increased Target to $260 on, Tuesday, April 28th, 2020
  • Brian Skorney of "Baird" Downgraded from Buy to Hold and Increased Target to $230 on, Friday, January 31st, 2020


These are the ratings of the 5 analyists that currently disagree with Matthew


  • Evan Seigerman of "Credit Suisse" Maintained at Buy with Increased Target to $298 on, Tuesday, April 21st, 2020
  • Gena Wang of "Barclays" Initiated at Buy on, Friday, March 20th, 2020
  • Alethia Young of "Cantor Fitzgerald" Reiterated at Buy with Increased Target to $275 on, Wednesday, March 11th, 2020
  • Ying Huang of "B of A Securities" Maintained at Strong Buy with Increased Target to $295 on, Friday, January 31st, 2020
  • Edward Tenthoff of "Piper Sandler" Maintained at Buy with Increased Target to $284 on, Monday, January 6th, 2020
Contributing Sources